David A. Siegel Voyager Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 58,600 shares of VYGR stock, worth $234,400. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,600

Holding current value

$234,400

% of portfolio

0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$2.96 - $4.71 $173,456 - $276,006	58,600 New	58,600 $270,000
Q1 2024 May 15, 2024	BUY	$7.15 - $10.84 $15,730 - $23,848	2,200 Added 14.38%	17,500 $162,000
Q4 2023 Feb 14, 2024	SELL	$6.28 - $8.81 $43,960 - $61,670	-7,000 Reduced 31.39%	15,300 $129,000
Q3 2023 Nov 14, 2023	SELL	$7.55 - $11.25 $61,910 - $92,250	-8,200 Reduced 26.89%	22,300 $172,000
Q2 2023 Aug 14, 2023	SELL	$6.94 - $13.99 $31,924 - $64,354	-4,600 Reduced 13.11%	30,500 $349,000
Q1 2023 May 15, 2023	BUY	$6.0 - $10.78 $117,600 - $211,288	19,600 Added 126.45%	35,100 $270,000
Q4 2022 Feb 14, 2023	SELL	$4.94 - $6.61 $82,992 - $111,048	-16,800 Reduced 52.01%	15,500 $94,000
Q3 2022 Nov 14, 2022	BUY	$5.57 - $7.47 $8,912 - $11,952	1,600 Added 5.21%	32,300 $191,000
Q2 2022 Aug 15, 2022	BUY	$4.82 - $10.09 $82,904 - $173,548	17,200 Added 127.41%	30,700 $181,000
Q1 2022 May 16, 2022	BUY	$2.75 - $9.44 $37,125 - $127,440	13,500 New	13,500 $103,000
Q4 2021 Feb 14, 2022	SELL	$2.47 - $5.55 $76,076 - $170,940	-30,800 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.63 - $4.12 $217,764 - $341,136	-82,800 Reduced 72.89%	30,800 $81,000
Q2 2021 Aug 16, 2021	SELL	$3.94 - $5.44 $248,614 - $343,264	-63,100 Reduced 35.71%	113,600 $469,000
Q1 2021 May 17, 2021	BUY	$4.61 - $9.04 $814,587 - $1.6 Million	176,700 New	176,700 $832,000
Q4 2020 Feb 16, 2021	SELL	$7.15 - $12.28 $279,565 - $480,148	-39,100 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$10.01 - $13.75 $241,241 - $331,375	-24,100 Reduced 38.13%	39,100 $417,000
Q2 2020 Aug 14, 2020	SELL	$8.05 - $14.21 $69,230 - $122,206	-8,600 Reduced 11.98%	63,200 $798,000
Q1 2020 May 15, 2020	SELL	$6.8 - $14.66 $139,400 - $300,530	-20,500 Reduced 22.21%	71,800 $657,000
Q4 2019 Feb 14, 2020	BUY	$12.82 - $16.85 $93,586 - $123,005	7,300 Added 8.59%	92,300 $1.29 Million
Q3 2019 Nov 14, 2019	SELL	$16.31 - $28.29 $272,377 - $472,443	-16,700 Reduced 16.42%	85,000 $1.46 Million
Q2 2019 Aug 14, 2019	BUY	$19.18 - $27.88 $30,688 - $44,608	1,600 Added 1.6%	101,700 $2.77 Million
Q1 2019 May 15, 2019	BUY	$8.0 - $19.66 $7,200 - $17,694	900 Added 0.91%	100,100 $1.92 Million
Q4 2018 Feb 14, 2019	SELL	$8.59 - $18.05 $10,308 - $21,660	-1,200 Reduced 1.2%	99,200 $932,000
Q3 2018 Nov 14, 2018	BUY	$17.11 - $21.74 $51,330 - $65,219	3,000 Added 3.08%	100,400 $1.9 Million
Q2 2018 Aug 14, 2018	BUY	$16.76 - $23.92 $1.46 Million - $2.08 Million	86,900 Added 827.62%	97,400 $1.9 Million
Q1 2018 May 15, 2018	BUY	$16.16 - $31.31 $169,680 - $328,755	10,500 New	10,500 $197,000

Others Institutions Holding VYGR

# of Institutions

122

Shares Held

29.9M

Call Options Held

121K

Put Options Held

16.2K

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $155M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account